Biogen challenges launch of Spinraza generic in Russia
US biotech major Biogen (Nasdaq: BIIB) is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent.
The generic was registered by the Russian company Generium in April 2024 and by the end of the second quarter of 2024 it had already taken up almost half of the total share of public procurement of drugs with the active ingredient nusinersen. At present the state's annual spending on the purchase of such drug exceeds a huge sum of 13 billion roubles ($152 million).
Biogen, protesting over this, filed a lawsuit against Generium on July 25, 2024. Details of the claim are not disclosed, but a spokesman of Biogen told the Russian Kommersant business paper that the dispute is related to Generium’s launch of the drug Lantesens, which is a generic of Spinraza and which, according to the American company, infringes its patent for Spinraza.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze